IL6 and COVID-19: In summary, although we found positive effects of nasal Foralumab as measured by decreases in IL-6 and CRP and improvement on lung CT scans in mild to moderate COVID-19 patients, our results must be taken with caution and we cannot conclude that nasal Foralumab has a beneficial effect in COVID-19 until larger studies are performed.